American Society for Clinical Laboratory Science

Session : ASCLS1301
Opening Keynote - An Emerging Professional Role for Laboratorians
Conference : 81st Annual Meeting
Speaker(s) :

Download Format(s) :
MP3,VIDEO

$25.00

Brian Jackson, MD, MS, FCAP Medical Director of Informatics ARUP Laboratories Department of Pathology, University of Utah

The diagnostic needs of primary care doctors and what labs might do to support them are essential to the appropriate care of patients and assuring patient safety. It is a little different focus than the usual within-lab quality management that we laboratory professionals are used to; the efforts should support getting the right test for the right patient which has safety implications. This will fit nicely with the need for clinical medicine to take better advantage of laboratory professionals knowledge, and the need for all of us as laboratory professionals to extend beyond the walls of the lab.

Session : ASCLS1302
Noroviruses: Challenges of the "Stomach Flu" Virus
Scientific Session 1
Conference : 81st Annual Meeting
Speaker(s) :

Download Format(s) :
MP3,VIDEO

$25.00

Hoonmo Koo, MD, MPH, Baylor College of Medicine

This presentation will provide an update regarding the epidemiology of norovirus gastroenteritis, highlighting emerging vulnerable populations including children, travelers, and the immunocompromised, the pathogenesis and host response to norovirus infections, and the current challenges for the diagnosis, treatment and prevention of norovirus infections.

Investment Return: Recognize the epidemiologic burden of noroviruses in the United States Describe the unique characteristics of norovirus pathogenesis that lead to widespread outbreaks Identify the diagnostic, therapeutic and preventative challenges of norovirus infections

Session : ASCLS1303
Accountable Care Organizations (ACOs) and the Role of the Medical Laboratory
Scientific Session 2
Conference : 81st Annual Meeting
Speaker(s) :

Download Format(s) :
MP3,VIDEO

$25.00

Rick Panning, MBA, MLS (ASCP)CM, Fairview Health Services

Accountable Care Organizations (ACOs) and other coordinated care models are being designed to focus on outcomes and the overall status of a population of patients for which an organization is responsible. Laboratory professionals have the opportunity to play a critical role in these organizations as improved outcomes and cost effectiveness will be a critical focus.

Investment Return: Define an Accountable Care Organization Explain three ways in which the medical laboratory can play an integral role in assuring quality and cost effective outcomes for our patients Examine how laboratory professionals should be involved in your organizations ACO strategy

Session : ASCLS1304
Mechanism of Action of Common Anti-leukemic Drugs
Scientific Session 3
Conference : 81st Annual Meeting
Speaker(s) :

Download Format(s) :
MP3,VIDEO

$25.00

Tim R. Randolph, PhD, MT (ASCP), Saint Louis University

The mechanism of action of several commonly used non-targeted antileukemic drugs (chemotherapy) will be discussed. In addition, the mechanism of action of a few targeted leukemia therapies will also be discussed and contrasted with the non-targeted therapies. Therapeutic sequeleae will be presented and linked to the drugs mechanism of action.

Investment Return: Compare and contrast the mechanism of action of classic chemotherapy with targeted therapeutic approaches Summarize the mechanism of action of at least 5 different categories of classic chemotherapeutic drugs Describe the molecular biology of 2 primary targeted anti-leukemic drugs

Session : ASCLS1305
Nanotechnology in Breast Cancer Therapy (AUDIO ONLY)
Scientific Session 4 (AUDIO ONLY)
Conference : 81st Annual Meeting
Speaker(s) :

Download Format(s) :
MP3

$25.00

Deborah Josko, PhD, The State University of New Jersey

In this presentation we will present the effect of various concentrations of the therapeutic drugs paclitaxel and ceramide on a triple negative breast cancer cell line in vitro. The effects of paclitaxel and ceramide encapsulated in nanoparticles will be examined.

Investment Return: Discuss the use of nanoparticles as a drug delivery system in cancer therapy Describe the protocol and assays used to determine the concentration dependence of the combined effects and therapeutic efficacy of paclitaxel and ceramide in vitro on the growth of a triple negative breast cancer cell line Examine the effects of drugs that are encapsulated in nanoparticles

Session : ASCLS1306
The Human Microbiome: An Underappreciated Organ Important for Human Health
Scientific Session 5
Conference : 81st Annual Meeting
Speaker(s) :

Download Format(s) :
MP3,VIDEO

$25.00

Joseph Petrosino, PhD, Baylor College of Medicine

The Alkek Center for Metagenomics and Microbiome Research at Baylor College of Medicine is advancing numerous human microbiome studies characterizing how commensal microorganisms interact with human tissues during the course of life. These studies will lead to new interventions and diagnostics for a variety of heritable and infectious diseases.

Investment Return: Define and discuss the human microbiome and metagenomics Discuss various impacts the microbiome has on human health Analyze multiple ways in which metagenomics may impact clinical diagnostics

Session : ASCLS1307
Herbal Medicine/Dietary Supplement and its Effects on Laboratory Testing
Scientific Session 6
Conference : 81st Annual Meeting
Speaker(s) :

Download Format(s) :
MP3,VIDEO

$25.00

George B. Kudolo, PhD, CPC, FACB, University of Texas Health Science Center

More than 50% of the US population ingest dietary supplements, classified as herbal medicines in other countries, which increase the risk of (a) adverse events from drug-herb interactions, (b) misinterpretation of clinical diagnostic tests and (c) false positive toxicology tests. This lecture will discuss selected supplements or herbal medicines.

Investment Return: Define briefly the purpose and main features of the Dietary Supplement Health and Education Act, 1994 of the 103rd Congress of the United States Describe the selected products known to cause drug-herb interactions with clinical side effects Discuss selected compounds known to produce abnormal chemistry test results or false-positive forensic toxicology test results

Session : ASCLS1308
Serum Free Light Chains for the Screening, Diagnosis, and Monitoring of Monoclonal Gammopathies
Conference : 81st Annual Meeting
Speaker(s) :

Download Format(s) :
MP3,VIDEO

$25.00

Scientific Session 7

Deborah J. Kuhn, PhD, The Binding Site, Inc.

This session will present the use of serum free light chains for the screening, diagnosis, and monitoring of monoclonal gammopathies and other plasma cell dyscrasias.

Investment Return: Explain the use of serum free light chains as biomarkers Discuss the use of serum free light chains for the diagnosis, screening, and monitoring of monoclonal gammopathies Evaluate how serum free light chains can be used in the riskstratification of monoclonal gammopathies of undermined significance (MGUS)

Session : ASCLS1309
Genomics as a Part of Integrated Health Care
Scientific Session 8
Conference : 81st Annual Meeting
Speaker(s) :

Download Format(s) :
MP3,VIDEO

$25.00

Ephrem Chin, MBA, MB (ASCP)CM, Baylor College of Medicine

The sequencing of the human genome has opened doors for new approaches to preventative healthcare, diagnostics, and treatment. Genetic research is now leading to a better understanding of the genetic components of diseases and introduced opportunities for creating new methods for screening, prevention, diagnosis and treatment of diseases.

estment Return: Discuss how advances in genomics have pushed the development of new methods for screening, prevention, diagnosis, and treatment of diseases Describe the next generation sequencing technologies, its use and limitations Analyze the issues relevant to the integration of genomics technologies to healthcare

Session : ASCLS1310
Healthcare Forum (AUDIO ONLY)
(AUDIO ONLY)
Conference : 81st Annual Meeting
Speaker(s) :

Download Format(s) :
MP3

$25.00

Moderator: Vince Stine, PhD, AACC

The 2013 symposia will focus on: the FDAs new policy on laboratory developed tests and its impact on medical device manufacturers and clinical laboratories; current CMS efforts to identify different payment models to cut health care spending and reduce utilization of services; CMS efforts to improve the competency of laboratory personnel; and a review and analysis of lab-related issues introduced in the 113th Congress.